Randomized Trial: Trastuzumab for 6 Months as Good as Treatment for 12 Months in Patients with HER2-positive Early Breast Cancer

17 Jun, 2019 | 01:30h | UTC

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial – The Lancet (free)

Commentaries: Is the duration of adjuvant trastuzumab debate still clinically relevant? – The Lancet (free) AND 6 months treatment with Herceptin is as good as 12 months for preventing breast cancer return – University of Warwick (free)

 

Join our WhatsApp group

Free Updates in All Specialties!

A daily update on the latest medical news, practice-changing trials and guidelines

Stay Updated in Your Specialty
No spam, just news
Unsubscribe with one click

 

Daily

 

Weekly or Less Often 
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •